readthroughSign in
Nov 12, 2026Weekly roundupUpdated

Regeneron registry update: new MUC16 trial added; HS, MASH, ALD, melanoma, obesity studies continue

Regeneron's clinical trial registry shows a newly posted update to a SMARCB1-deficient malignancy study alongside continuing MASH, ALD, HS, melanoma, and obesity trials.

Regeneron's registry records show updates across six studies this week, ranging from an oncology collaboration with M.D. Anderson to several liver and metabolic disease programs.

  • A Phase 2 trial of ubamatamab, alone or combined with cemiplimab, is recruiting patients with renal medullary carcinoma or epithelioid sarcoma. The trial seeks to find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES)1, with enrollment estimated at 40 participants1 and M.D. Anderson Cancer Center as lead sponsor alongside Regeneron as collaborator.
  • A Phase 2 trial of ALN-HSD, an siRNA gene-silencing drug for MASH in patients with genetic risk factors, is active but not recruiting. The study aims to see the effect of the study drug on lessening liver scarring related to MASH2, with enrollment estimated at 120 participants randomized 1:1 between ALN-HSD and placebo2.
  • A new Phase 2 study of ALN-CIDEB in alcohol-associated liver disease (ALD) and MetALD is not yet recruiting. The trial will compare 2 different dose regimens of ALN-CIDEB with placebo to understand how well ALN-CIDEB works to lower the amount of fat in the liver3, with enrollment estimated at 120 participants3 and a start estimated for 2026-12-09.
  • The Phase 2 COURAGE trial testing trevogrumab, with or without garetosmab, alongside semaglutide for obesity has completed. The study examined how safe and effective the study drug is when combined with Wegovy4, with actual enrollment of 1005 participants4.
  • The Phase 2 olatorepatide trial in hidradenitis suppurativa with overweight or obesity is recruiting, testing the drug to see if it helps improve their HS symptoms and quality of life and helps support weight loss5, with enrollment estimated at 300 participants5.
  • The long-term follow-up study of fianlimab plus cemiplimab in melanoma patients remains active but not recruiting, tracking patients who had previously been treated with fianlimab and cemiplimab in the study called R3767-ONC-1613 (NCT03005782)6, with actual enrollment of 28 participants6.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.